Inhibition of the glycolytic key enzyme LDHA or use of LDH inhibitors (such as sodium oxalate) can enhance CD8+ T cell killing ability, reverse tumor immune escape, and produce a synergistic effect with anti-PD-1 therapy. The gene discussed is CD8A; the disease is neoplasm.